Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets

Trofimov, Valentin, Kicka, Sébastien, Mucaria, Sabrina, Hanna, Nabil, Ramon-Olayo, Fernando, Del Peral, Laura Vela Gonzalez, Lelièvre, Joël, Ballell, Lluís, Scapozza, Leonardo, Besra, Gurdyal S., Cox, Jonathan A.G. and Soldati, Thierry (2018). Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets. Scientific Reports, 8 (1),

Abstract

Tuberculosis remains a serious threat to human health world-wide, and improved efficiency of medical treatment requires a better understanding of the pathogenesis and the discovery of new drugs. In the present study, we performed a whole-cell based screen in order to complete the characterization of 168 compounds from the GlaxoSmithKline TB-set. We have established and utilized novel previously unexplored host-model systems to characterize the GSK compounds, i.e. the amoeboid organisms D. discoideum and A. castellanii, as well as a microglial phagocytic cell line, BV2. We infected these host cells with Mycobacterium marinum to monitor and characterize the anti-infective activity of the compounds with quantitative fluorescence measurements and high-content microscopy. In summary, 88.1% of the compounds were confirmed as antibiotics against M. marinum, 11.3% and 4.8% displayed strong anti-infective activity in, respectively, the mammalian and protozoan infection models. Additionally, in the two systems, 13-14% of the compounds displayed pro-infective activity. Our studies underline the relevance of using evolutionarily distant pathogen and host models in order to reveal conserved mechanisms of virulence and defence, respectively, which are potential "universal" targets for intervention. Subsequent mechanism of action studies based on generation of over-expresser M. bovis BCG strains, generation of spontaneous resistant mutants and whole genome sequencing revealed four new molecular targets, including FbpA, MurC, MmpL3 and GlpK.

Publication DOI: https://doi.org/10.1038/s41598-018-22228-6
Divisions: Life & Health Sciences
Life & Health Sciences > Applied Health Research Group
Additional Information: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Te images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2018
Uncontrolled Keywords: General
Full Text Link:
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
https://www.nat ... 018-22228-6.pdf (Publisher URL)
Published Date: 2018-03-02
Authors: Trofimov, Valentin
Kicka, Sébastien
Mucaria, Sabrina
Hanna, Nabil
Ramon-Olayo, Fernando
Del Peral, Laura Vela Gonzalez
Lelièvre, Joël
Ballell, Lluís
Scapozza, Leonardo
Besra, Gurdyal S.
Cox, Jonathan A.G. ( 0000-0001-5208-4056)
Soldati, Thierry

Download

[img]

Version: Published Version

License: Creative Commons Attribution

| Preview

Export / Share Citation


Statistics

Additional statistics for this record